Drugs / NUMIDARGISTAT
NUMIDARGISTAT
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03910530 | Jul 2019 → Dec 2021 | cancer, metastatic neoplasm | Incyte Biosciences Japan GK | Completed | No outcome recorded |
| Phase 1 | NCT02903914 | Sep 2016 → Apr 2020 | colorectal cancer, gastric cancer, head and neck cancer, lung cancer +5 | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03837509 | Sep 2019 → Apr 2022 | refractory plasma cell neoplasm | Incyte Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03361228 | Mar 2018 → Mar 2019 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03314935 | Nov 2017 → Nov 2022 | biliary tract cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer +1 | Incyte Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-01 | Molecure S.A. | Results First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy molecure.com ↗
INCB1158 was well tolerated and inhibited plasma arginase activity, inducing increased plasma arginine levels at all doses tested. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-10-01 | Molecure S.A. | First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy molecure.com ↗ |
| 2017-01-30 | Incyte Corporation | Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor incyte.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUMIDARGISTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4218271 ↗ |
| Known as | Arginase inhibitor incb001158 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4218271 ↗ |
| Known as | CB-1158 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4218271 ↗ |
| Known as | INCB001158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03837509 ↗ |
| Action | Inhibit | “Consistent with arginase inhibition activity, plasma arginine dose-dependently increased.” PMID 39886141 ↗ May 2024 |
| Modality | Small molecule | — CHEMBL4218271 ↗ |
| Route | Oral | “INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks.” PMID 39886141 ↗ May 2024 |